Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025
Rhea-AI Summary
Pulmonx (NASDAQ: LUNG), a leader in minimally invasive lung disease treatments, has scheduled its Q2 2025 financial results announcement for July 30, 2025, after market close. Management will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can access the live and archived webcast through the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – LUNG
On the day this news was published, LUNG gained 6.19%, reflecting a notable positive market reaction. Argus tracked a peak move of +14.4% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $8M to the company's valuation, bringing the market cap to $133M at that time.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Wednesday, July 30, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraXTM Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraXTM is a trademark of Pulmonx Corporation.
Investor Contact
Jeremy Feffer
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When will Pulmonx (LUNG) release Q2 2025 earnings?
What time is the Pulmonx (LUNG) Q2 2025 earnings call?
How can I access Pulmonx (LUNG) Q2 2025 earnings call?
What does Pulmonx (LUNG) company do?
